MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC)

BACKGROUND: Pain symptoms in the upper abdomen and back are prevalent in 80% of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), where the current standard treatment is a systemic therapy consisting of at least doublet-chemotherapy for fit patients. Palliative low-dose radiotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavic, M., Niyazi, M., Wilke, L., Corradini, S., Vornhülz, M., Mansmann, U., Al Tawil, A., Fritsch, R., Hörner-Rieber, J., Debus, J., Guckenberger, M., Belka, C., Mayerle, J., Beyer, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788088/
https://www.ncbi.nlm.nih.gov/pubmed/35078490
http://dx.doi.org/10.1186/s13014-022-01988-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788088/
https://www.ncbi.nlm.nih.gov/pubmed/35078490
http://dx.doi.org/10.1186/s13014-022-01988-6

Ejemplares similares